493
Participants
Start Date
April 10, 2019
Primary Completion Date
March 12, 2024
Study Completion Date
May 19, 2024
SaiLuoTong capsule
500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
placebo
500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
The First Hospital of Changsha, Changsha
Xuan Wu Hospital of Capital Medical University, Beijing
Peking University Shougang Hospital, Beijing
Taizhou Hospital of Chinese Medicine, Taizhou
Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin
The Central Hospital of Lishui City, Lishui
Jiujiang University Clinical Medical College ▪ Jiujiang University Hospital, Jiujiang
Yueyang Second People's Hospital, Yueyang
The First People's Hospital of Luoyang, Luoyang
The First affiliated Hospital of Nanyang Medical college, Nanyang
Nanyang Second People's Hospital, Nanyang
Xianyang Hospital of Yan'an University, Xianyang
Xiyuan Hospital, Beijing
Affiliated Hospital of Hebei University, Baoding
The Fourth Hospital of Medical University, Harbin
Xiangya Boai Rehability Hospital, Changsha
Inner Mongolia International Mongolian Hospital, Hohhot
Nanchang Hongdu Hospital of TCM, Nanchang
Jinzhong First People's Hospital, Jinzhong
Yuncheng Central Hospital, Yuncheng
The Second people's Hospital of Neijiang, Neijiang
The Second Hospital of Xingjiang Medical University, Ürümqi
Affiliated Hospital of Chengde Medical College, Chengde
Handan First Hospital, Handan
Hebei Central Hospital of petrochina, Langfang
The First Hospital of Hebei Medical University, Shijiazhuang
The Third Hospital of Hebei Medical University, Shijiazhuang
Baogang Hospital, Baotou
Changzhi People's Hospital, Changzhi
Shineway Pharmaceutical Co.,Ltd
INDUSTRY